QUALITY OF LIFE IN CHILDREN WITH JUVENILE RHEUMATOID ARTHRITIS TREATED WITH INFLIXIMAB
Abstract
Key words: children, juvenile rheumatoid arthritis, quality of life, infliximab.
About the Authors
R.V. DenisovaRussian Federation
E.I. Alexeeva
Russian Federation
V.Yu. Al'bitsky
Russian Federation
I.V. Vinyarskaya
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
A.M. Alekseeva
Russian Federation
V.V. Chernikov
Russian Federation
References
1. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди. 2007.
2. Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей. Качество жизни. М.: Медицина. 2008. С. 14–17.
3. Яковлева Л.В. Психологические особенности личности детей с ювенильным ревматоидным артритом. РПЖ. 1998; 6: 20–21.
4. Huygen A.C., Kuis W., Sinnema G. Psychological, behavioral and social adjustment in children and adolescents with juvenile chronic arthritis. Ann. Rhem. Dis. 2000; 59 (4): 276–282.
5. Selvaag A.M., Flat B., Lien G. et al. Measuring health in early juvenile idiopathic arthritis: determinants and responsiveness of the child health questionnaire. J. Rheumatol. 2003; 30 (7): 1602–1610.
6. Людкевич О.М., Бабикова И.В., Макарова В.И., Изучение качества жизни детей с ювенильным хроническим артритом. Тезисы научно–практической конференции «Новое в ревматологии». Тюмень. 2006. С. 35.
7. Людкевич О.М. Бабикова И.В., Макарова В.И. Изучение качества жизни ребенка в практике педиатра-ревматолога. Экология человека. 2006; 4: 23–27.
8. Кузьмина Н.Н., Никишина И.П., Шайков А.В. и др. Российский адаптированный вариант опросников для оценки качества жизни и состояния здоровья детей с ювенильными хроническими артритами. Научно–практическая ревматология. 2002; 2: 40-47.
9. Sawyer M.G., Whitham J.N., Roberton D.M. et al. The relationship between health – related quality of life, pain and coping strategies in juvenile idiopathic arthritis. Rheumatology. 2004; 43 (3): 325–330.
10. Feldman M., Brennan F., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996; 14: 397–440.
11. Dinarello C.A., Moldawer L.L. Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primer for clinicians. 2nd ed. NY: Amgen. Inc. 2000. 282 p.
12. Lipsky P.E, Desiree M.D., van der Heijde et.all Infliximab and Methotrexate in the treatment of rheumatoid arthritis. The New England. Journal of Medicine. 2000; 343: 1594–1601.
13. Elliot M.J., Maini R.N., Feldmann M., et al. Randomized double blind comparision of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344: 1105–1110.
14. Maini R.N., Breedveld F.C., Kalden J.R. et al. Therapeutic efficacy of multiplay intravenous infusion of anti-tumor necrosis factor α monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1552–1563.
15. Лукина Г.В. Антицитокиновая терапия ревматоидного артрита. Автореф. дис…докт. мед. наук. М. 2004.
16. Ruperto N, Lovell DJ, Cuttica R, et al. Randomized trial of infliximab (IFX) plus methotrexate (MTX) for the treatment of polyarticular juvenile rheumatoid arthritis (JRA) [poster]. European League Against Rheumatism. Vienna, Austria. June 8-11, 2005. Poster SAT0325.
17. Vougiouka O., Rizou S., Grafakou O. Infliximab and etanercept in the treatment of juvenile idiopathic arthritis. The Athens experience [abstract]. Ann. Rheum. Dis. 2001; 60: 17–52. Abstract P176.
18. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.
19. Scarazatti M., Beltramelli M., Dell’Era L. et al. Infliximab in juvenile idiopathic arthritis [abstract]. Ann. Rheum. Dis. 2001; 60: 17–52. Abstract P180.
20. Vinje O., Obiora E., Forre O. Juvenile chronic polyarthritis treated with infliximab [abstract]. Ann. Rheum. Dis. 2000; 59: 713–749. Abstract 11.25.
21. Gerloni V., Pontikaki I., Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-TNF-α monoclonal antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis. Results of an open label prospective study. Arthritis Rheum. 2005; 52 (2): 548–553.
22. Chaturvedi V.P. Pilot study of chimeric monoclonal anti-tumor necrosis factor alpha anti-body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis [abstract]. American College of Rheumatology 66th Annual Scientific Meeting. October 24–25, 2002. New Orleans, LA. Abstract LB12.
23. Honkanen V.E., Tynjala P., Vahasalo P. et al. Infliximab in juvenile arthritis: 1-year follow-up [abstract]. American College of Rheumatology 66th Annual Scientific Meeting. October 24–25, 2002. New Orleans, LA. Abstract 1272.
24. Honkanen V., Lappi M., Koskinen L. et al. Infliximab treatment in the refractory chronic uveitis of juvenile idiopathic arthritis (JIA) [abstract]. American College of Rheumatology 65th Annual Scientific Meeting. November 11–16, 2001. San Francisco, CA. Abstract 1438.
25. Masatlioglu S., Gogus F., Cevirgen D. et al. Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum. 2002; 46: 481.
26. Crandall W.V., Mackner L.M. Infusion reactions to infliximab in children and adolescents: frequency, outcome and predictive model. Aliment. Pharmacol. Ther. 2003; 17: 75–84.
27. Elliot M.J., Woo P., Charles P. et al. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumor necrosis factor-α (cA2). Br. J. Rheumatol. 1997; 36: 589–593.
28. Billiau A.D., Cornillie F., Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J. Rheumatol. 2002; 29: 1111–1114.
29. Kimura Y., Imundo L.F., Li S.C. High dose infliximab in the treatment of resistant systemic juvenile rheumatoid arthritis [abstract]. American College of Rheumatology 65th Annual Scientific Meeting. November 11–16, 2001. San Francisco, CA. Abstract 1316.
30. Foeldvari I., Kruger E., Schneider T. Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis. Ann. Rheum. Dis. 2003; 62: 908–909.
31. Tutar E., Ekici F., Nacar N. et al. Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatol. 2004; 43: 674–675.
32. Armbrust W., Kamphuis S.S., Wolfs T.W. et al. Tuberculosis in a nine year old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatol. 2004; 43: 527–529.
33. Алексеева Е.И., Алексеева А.М., Бзарова Т.М., Валиева С.И., Афонина Е.Ю. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 2: 20–30.
34. Ruperto N., Lovell D. J., Cuttica R. et al. A randomized, placebo controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56: 3096–3106.
Review
For citations:
Denisova R., Alexeeva E., Al'bitsky V., Vinyarskaya I., Valieva S., Bzarova T., Alekseeva A., Chernikov V. QUALITY OF LIFE IN CHILDREN WITH JUVENILE RHEUMATOID ARTHRITIS TREATED WITH INFLIXIMAB. Current Pediatrics. 2008;7(6):30-38.
Email this article 
